Grupo Farmacéutico Guangzhou, S.A.
Contact information
- Biodrugs
- Biomarkers
- Stem cells
- Cell cultures
- Biological defense
- In vitro diagnostics
- Diagnostic imaging
- Medical devices
- Drug delivery
- Drug development
- Drug discovery
- Screening
- Cellular Therapy
- Gene Therapy
- Analgesia & Pain
- Cosmetics
- Dermatology
- Musculoskeletal system
- Cardiovascular diseases and circulatory system
- Genetic and rare diseases
- Infectious diseases
- Inflammatory diseases
- Gynaecology and obstetrics
- Immunology
- Odontology
- Ophtalmology and optometry
- Oncology
- Blood and lymphatic system
- Digestive system and hepatology
- Kidney and genitourinary system
- Central nervous system
- Respiratory and pulmonary system
- Metabolic disorders / Endocrinology
- Biologic control (plagues..) and bioestimulants of crops
- Animal health / Veterinary
- Animal Food / Feed
- Functional Food
- APIs and green chemistry
- Fermentation or biocatalysis
- CRO / CMO / SMO
- Maintenance of cell cultures
Guangzhou Pharmaceutical Holdings Limited (GPHL), one of the largest
pharmaceutical enterprises in China, is a large-scale enterprise group integratingscience, industry and trade.
Its core business focuses on the manufacture and sales of Chinese and Western patent medicines. GPHL also conducts R&D, manufacturing and sales of chemicalraw materials (APIs), natural medicines, biological medicines and API intermediates;wholesale, retail and import & export of Western medicines, Traditional Chinesemedicines and medical devices; R&D, production and sales of health & wellnessproducts; as well as investments in health-related sectors including medical services, health management, wellness and elderly care services.
GPHL owns 13 China Time-honored Brands, 11 of which have a history of over 100 years. It also holds 13 national and provincial Intangible Cultural Heritage (ICH) items and 10 China Well-known Trademarks. GPHL boasts more than 2,000 product registration certificates and over 30 products with annual revenue exceeding RMB 100 million. Its renowned brands include Chenliji, honored as the world’s oldest continuously operating pharmaceutical factory, and Wanglaoji, the founding brand of herbal tea and a leading domestic beverage brand in China. GPHL holds a controllingstake in the listed company Baiyunshan and an equity stake in Kangmei.
In 2021, GPHL became the world’s first and only Fortune Global 500 companywith Traditional Chinese Medicine (TCM) as its core business. It has been included in the list for 6 consecutive years and currently ranks 467th.
GPHL’s core business focuses on the manufacture and sales of Chinese and Western patent medicines. GPHL also conducts R&D, manufacturing and sales of chemicalraw materials (APIs), natural medicines, biological medicines and API intermediates;wholesale, retail and import & export of Western medicines, Traditional Chinesemedicines and medical devices; R&D, production and sales of health & wellnessproducts; as well as investments in health-related sectors including medical services, health management, wellness and elderly care services.
The Group directs its interests towards the manufacture and sales of Chinese and Western patent medicines; the R&D, manufacturing and sales of chemical APIs, natural medicines, biological medicines, and API intermediates; the wholesale, retail, and import/export of Western medicines, TCM, and medical devices; the R&D, production, and sales of health & wellness products; as well as investments in health‑related fields such as medical services, health management, wellness, and elderly care.